Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells

International Journal of Cancer

Volumn 140, Issue 1, 2017, Pages 109-119

  Kim, Hee Jun ^a,b   Min, Ahrum ^c,d   Im, Seock Ah ^b,c,d   Jang, Hyemin ^c   Lee, Kyung Hun ^b,c,d   Lau, Alan ^e   Lee, Miso ^c   Kim, Seongyeong ^c   Yang, Yaewon ^b,c   Kim, Jungeun ^c   Kim, Tae Yong ^b,c,d   Oh, Do Youn ^b,c,d   Brown, Jeffrey ^e   O'Connor, Mark J ^e   Bang, Yung Jue ^b,c,d  

^a Chung Ang University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e ASTRAZENECA   (United Kingdom)

Author keywords

ATR inhibitor; breast cancer; DNA damage response; homologous recombination

Indexed keywords

ANTINEOPLASTIC AGENT; ATR PROTEIN; AZD 6738; CHECKPOINT KINASE 1; CISPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; ATM PROTEIN; ATR PROTEIN, HUMAN; AZD6738; CHEK1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFOXIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MTT ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHECKPOINT KINASE 1; CISPLATIN; DNA REPAIR; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, ERBB-2; SULFOXIDES;

EID: 84992416945     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30373     Document Type: Article

References (32)

1. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341–54.
2. Davis JD, Lin SY. DNA damage and breast cancer. World J Clin Oncol 2011;2:329–38.
3. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005;5:388–93.
4. Hay T, Matthews JR, Pietzka L, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850–5.
5. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109–15.
6. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5–23.
7. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177–96.
8. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007;28:739–45.
9. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nature Reviews Molecular Cell Biology 2008;9:616–27.
10. Zou L. Single- and double-stranded DNA: building a trigger of ATR-mediated DNA damage response. Genes Dev 2007;21:879–85.
11. Gamper AM, Rofougaran R, Watkins SC, et al. ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage. Nucleic Acids Res 2013;41:10334–44.
12. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003;17:615–28.
13. Niida H, Katsuno Y, Banerjee B, et al. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol 2007;27:2572–81.
14. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009;21:245–55.
15. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864–70.
16. Yan Y, Hein AL, Greer PM, et al. A novel function of HER2/Neu in the activation of G2/M checkpoint in response to gamma-irradiation. Oncogene 2015;34:2215–26.
17. Boone JJ, Bhosle J, Tilby MJ, et al. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 2009;8:3015–23.
18. Nowsheen S, Cooper T, Bonner JA, et al. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res 2012;72:4796–806.
19. Franke TF, Kaplan DR, Cantley LC, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997;275:665–8.
20. Foote KM, Lau A, Nissink JW. Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. Future Med Chem 2015;7:873–91.
21. Min A, Im SA, Yoon YK, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther 2013;12:865–77.
22. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440–6.
23. Kang S, Min A, Im SA, et al. TGF-beta Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. Cancer Res Treat 2015;47:101–9.
24. Ruzankina Y, Pinzon-Guzman C, Asare A, et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 2007;1:113–26.
25. Eykelenboom JK, Harte EC, Canavan L, et al. ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. Cell Rep 2013;5:1095–107.
26. Jiang K, Pereira E, Maxfield M, et al. Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J Biol Chem 2003;278:25207–17.
27. Toulany M, Lee KJ, Fattah KR, et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 2012;10:945–57.
28. Sahlberg SH, Gustafsson AS, Pendekanti PN, et al. The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol 2014;35:3525–34.
29. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013;73:3683–91.
30. Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002;277:12710–7.
31. Golding SE, Rosenberg E, Neill S, et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 2007;67:1046–53.
32. Marampon F, Gravina GL, Di Rocco A, et al. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 2011;10:159–68.